WATCH ZELLUNA ON DNB’S WEBCAST – Why TCR-NK Is Uniquely Positioned to Solve the Biggest Challenges in Cell Therapy
“We’re channeling the curative potential of cell therapies to treat solid cancers — at global scale.”
— Namir Hassan, CEO, Zelluna
In this episode of the DNB Webcast, Zelluna’s CEO Namir Hassan shares:
• Why TCR-NK could be the next major leap in cell therapy — built to overcome the limitations of today’s approaches
• How small, high-impact patient data sets are driving both approvals and high value deals — and what this means for patients and investors
• Zelluna’s de-risked path to the clinic — with experienced leadership, a strong IP position, and manufacturing secured (as announced yesterday)
• Zelluna’s dominating IP capturing the entire therapeutic field – what this could mean in terms of potential value unlocked
• What to watch in 2025 and beyond as we advance our lead TCR-NK asset into clinical development
Thanks to DNB and Marius Brun Haugen for the discussion.
Watch the episode HERE
Pioneering novel cell therapies for the treatment of cancer patients
Cell Therapies Can “Cure” Cancers
Cell therapies have delivered “cures” in certain late-stage cancer patients with multiple approved treatments mainly for liquid cancers. Several cell therapy products have been approved by regulatory authorities with data from less than 100 patients.
Solid Cancers remain a major challenge
Whilst there has been progress, successes in liquid cancers have not translated into solid cancers which represents by far the largest cancer burden and remains an unsolved challenge
Zelluna targets Solid Cancers
Zelluna is developing a unique and proprietary TCR-NK cell therapy platform.
TCR-NK therapies are designed to overcome the current challenges of treating solid cancers and can potentially be used to treat a range of solid cancers with unmet medical need in high value markets.
Saving life through innovative cancer targeted therapies
Zelluna’s mission is to eliminate solid cancers by unleashing the most powerful elements of the immune system through pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell therapies. The team comprises experienced biotech entrepreneurs that have taken immune-oncology projects from inception through to the clinic and supported by a highly experienced international board
